Abstract
Neglected tropical diseases are responsible for considerable morbidity and mortality in low-income populations. International efforts have reduced their global burden, but transmission is persistent and case-finding-based interventions rarely target asymptomatic individuals. We develop a generic mathematical modelling framework for analysing the dynamics of visceral leishmaniasis in the Indian sub-continent (VL), gambiense sleeping sickness (gHAT), and Chagas disease and use it to assess the possible contribution of asymptomatics who later develop disease (pre-symptomatics) and those who do not (non-symptomatics) to the maintenance of infection. Plausible interventions, including active screening, vector control and reduced time to detection, are simulated for the three diseases. We conclude that currently available tools could bring new infections under control for gHAT and Chagas disease – albeit over a long period of time for Chagas disease – but that VL will be more difficult to control with existing interventions. gHAT protocols that allow for treatment of parasitologically positive asymptomatics result in better control of infection compared to syndromic diagnosis required for VL. This work highlights that the high asymptomatic contribution to transmission for Chagas and gHAT and the apparently high basic reproductive number of VL may greatly undermine long-term control, but that precise predictions are hampered by uncertainty in natural history.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors gratefully acknowledge funding of the NTD Modelling Consortium by the Bill and Melinda Gates Foundation OPP1053230 (in partnership with the Task Force for Global Health), OPP1184344, OPP1177824 and INV-005121. TDH also acknowledges Institute funding from the Li Ka Shing Foundation. The views, opinions, assumptions or any other information set out in this article are solely those of the authors and should not be attributed to the funders or any person connected with the funders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors declare no competing interests
Data Availability
Data is available as supplementary information, and code available on request
